GlassScriptPhysician profile
Sara Danielle Bland
NPI 1043914765
$556.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $397 · 2024: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $134.15 | 2023-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $110.15 | 2023-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $79.62 | 2023 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $47.51 | 2023 | |
| Abbvie INC. | $42.13 | 2024 | |
| Dexcom, INC. | $39.65 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $21.80 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.61 | 2023 | Quviviq |
| Corium, LLC | $16.83 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $15.03 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2023 | Breztri |
| Esperion Therapeutics, INC. | $13.14 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Bland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.